- Home
- MATH vs AVTX Comparison
MATH vs AVTX Comparison
Compare MATH & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATH
- AVTX
- Stock Information
- Founded
- MATH 2015
- AVTX 2011
- Country
- MATH Hong Kong
- AVTX United States
- Employees
- MATH N/A
- AVTX N/A
- Industry
- MATH Finance/Investors Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MATH Finance
- AVTX Health Care
- Exchange
- MATH Nasdaq
- AVTX Nasdaq
- Market Cap
- MATH 60.8M
- AVTX 57.4M
- IPO Year
- MATH N/A
- AVTX 2015
- Fundamental
- Price
- MATH $3.22
- AVTX $4.00
- Analyst Decision
- MATH
- AVTX Strong Buy
- Analyst Count
- MATH 0
- AVTX 6
- Target Price
- MATH N/A
- AVTX $34.20
- AVG Volume (30 Days)
- MATH 193.2K
- AVTX 62.6K
- Earning Date
- MATH 01-01-0001
- AVTX 05-12-2025
- Dividend Yield
- MATH N/A
- AVTX N/A
- EPS Growth
- MATH N/A
- AVTX N/A
- EPS
- MATH 0.17
- AVTX N/A
- Revenue
- MATH $31,399,049.00
- AVTX $441,000.00
- Revenue This Year
- MATH N/A
- AVTX N/A
- Revenue Next Year
- MATH N/A
- AVTX N/A
- P/E Ratio
- MATH $19.30
- AVTX N/A
- Revenue Growth
- MATH 291.58
- AVTX N/A
- 52 Week Low
- MATH $0.80
- AVTX $3.39
- 52 Week High
- MATH $3.23
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- MATH 74.97
- AVTX 43.03
- Support Level
- MATH $2.79
- AVTX $3.43
- Resistance Level
- MATH $3.08
- AVTX $4.03
- Average True Range (ATR)
- MATH 0.33
- AVTX 0.36
- MACD
- MATH 0.06
- AVTX 0.07
- Stochastic Oscillator
- MATH 99.11
- AVTX 59.80
About MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).